Exclusive Statistical Report On Paracetamol Infusion Market 2021: Industry To Observe Strong Development With Top Key Vendors (Altan Pharma Limited, Sanofi, Pfizer, Amgen)

Precision Business Insights published a research report on “Global Paracetamol Infusion Market: By Application (Fever, Pain, Patent Ductus Arteriosus, and Others) and Geography- Global/Region/Country Forecast to 2027”

Quick Pain Relief and Less Price of the Drug is Driving the Global Market
Paracetamol is the most preferred drug worldwide. It is an over the counter drug and can be taken in combination with other drugs for the treatment of severe pain such as cancer pain. This drug is safe in lower dose. Pregnant lady can also consume it in fewer doses as it does not give side effects. It is the most used drug for fever as well as pain. It is also known as acetaminophen. It is hugely used as a pain killer drug. Pain relieving property of this drug drives the global market hugely. This drug is taken for severe pain like pain felt after surgery and cancer pain when consumed in combination with opioid pain medication. Effect of this pain killer lasts for two to four hours. This pain killer drug is seen in the List of Essential Medicines of World Health Organization, which lists the most secure and efficient medicines required in a health system. Furthermore, the low price of medicine also boosts the growth of the market in under developed region.

View Detailed Report Description https://precisionbusinessinsights.com/market-reports/paracetamol-infusion-market/

Asia Pacific witnesses larger market revenue share in Global Paracetamol Infusion Market
Asia pacific witnessed larger revenue share in global paracetamol infusion market recording significant CAGR rate due to the significant factors such as presence of industry players, growing aging population, less price of drug and fast relief from pain and fever. Paracetamol Infusion market in North America is experiencing notable rate because of its popularity and less price. It costs almost US$0.04 for every dose in the U.S. It was the 17th most approved drug in the U.S. recording more than 29 million prescriptions. Market in Europe is also growing at significant rate. Costs vary from country to country in Europe. Low-cost prices for ten doses could reach €1.97 in Germany, €0.54 in Portugal, €0.91 in France.

Request sample report https://precisionbusinessinsights.com/request-sample?product_id=37925

Competitive Assessment
Some of the major industry players working in Paracetamol infusion market are Altan Pharma Limited (Ireland), Unital Pharmaceuticals (India), Stellar- Bio Labs (India), Sun Pharma (India), Novartis, Cipla (India), Pfizer, Amgen, Inc and Sanofi. Global paracetamol infusion market is surging due to the effective strategies followed by the key players of this market, which include collaborations and product approvals. For example, Altan Pharma Limited submitted a New Drug Application for its formulation of acetaminophen solution for infusion to the United States Food and Drug Administration (FDA).

Contact:
Mr. Satya
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.